Candesartan in nephrological practice

Ya.A. Dombrovskyi, D.D. Ivanov

Abstract


First-line drugs in the treatment of hypertension in patients with chronic kidney disease is an angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. The topic of the article is devoted to comparative characteristics of these groups of drugs for use in patients with hypertension associated with renal disease. The main part of the article is an analysis of pharmacodynamics, efficacy, safety and expediency of candesartan, angiotensin II receptor blocker.


Keywords


arterial hypertension; chronic kidney disease; angiotensin-converting enzyme inhibitors; angiotensin II receptor blockers; candesartan

References


Unger T., Culman J., Gohlke P. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence // J. Hypertens. — 1998. — 16 (Suppl 7). — S3-9.

http://bestpractice.bmj.com/best-practice/monograph/530.html

Parmley W.W. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection // Am. J. Med. — 1998. — 105 (Suppl 1A). — 27S-31S.

Husain A. The chymase-angiotensin system in humans: editorial review // J. Hypertens. — 1993. — 11. — 1155-9.

Kjeldsen S.E., Stalhammar J., Hasvold P. et al. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension // Journal of Human Hypertension. — 2010. — 24. — P. 263-273.

Zheng Z., Shi H., Jia J., Li D., Lin S. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension // Journal of the Renin-Angiotensin-Aldosterone System. — 2011. — Published online March 18, 1470320310391503.

Rossing K., Christensen P., Hansen B. et al. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study // Diabetes Care. — 2003. — 26. — 150-155.

Schmieder E., Klingbeil A., Fleischmann E. et al. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study // J. Am. Soc. Nephrol. — 2005. — 16. — 3038-3045.

Burgess Е., Muirhead N., de CotretР. еt al. Supramaximal Dose of Candesartan in Proteinuric Renal Disease // J. Am. Soc. Nephrol. — 2009 April. — 20 (4). — 893-900.

Okura T., Kojima M., Machida H. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria // Journal of Human Hypertension. — 2012. — 26. — 214-21.

Ducharme A., Swedberg K., Pfeffer M.A. et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program // Am. Heart. J. — 2006. — Vol. 151, № 5. — P. 985-991.

Lindholm L.H., Persson M., Alaupovic P., Carlberg B., Svensson A., Samuelsson O. Antihypertensive Treatment and Lipid Profile in North of Sweden Efficacy Evaluation Study // J. Hypertens. — 2003, Aug. — 21 (8). — 1563-74.

Carl Erik Mogensen, Steen Neldam, Ilkka Tikkanen, Shmuel Oren, Reuven Viskoper, Richard W. Watts, Mark E. Cooper. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinoprilmicroalbuminuria (CALM) study // BMJ. — 2000. — 321 doi: http://dx.doi.org/10.1136/bmj.321.7274.1440 (Published 9 December 2000).

Yasuno S., Ueshima K., Oba K., Fujimoto A., Hirata M., Ogihara T., Saruta T., Nakao K. Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial // Diabetes Care. — 2010 May. — 33 (5). — 1122-7. doi: 10.2337/dc09-1447. Epub 2010 Feb 25.

Ogihara T., Ueshima K., Nakao K., Fukiyama K., Oba K., Yasuno S., Fujimoto A., Sato T., Matsuoka H., Saruta T. CASE-J Ex Study Group. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex) // Hypertens Res. — 2011 Dec. — 34 (12). — 1295-301. doi: 10.1038/hr.2011.120. Epub 2011 Aug 11.

Fukui T., Rahman M., Hayashi K., Takeda K., Higaki J., Sato T., Fukushima M., Sakamoto J., Morita S., Ogihara T., Fukiyama K., Fujishima M., Saruta T. CASE-J Study Group. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods // Hypertens. Res. — 2003 Dec. — 26 (12). — 979-90.

Suzuki T., Nozawa T., Fujii N., Sobajima M., Ohori T., Shida T., Matsuki A., Kameyama T., Inoue H. Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease // Coron. Artery Dis. — 2011 — 22. — P. 352-35.

Zanchetti A., Ruilope L.M. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? // J. Hypertens. — 2002 Nov. — 20 (11). — 2099-110.

Засновані на доказах рекомендації 2014 року з лікування високого артеріального тиску в дорослих осіб. Звіт члені вробочої групи, обраних до складу Восьмого національного об’єднаного комітету (Eighth Joint National Committee, JNC 8) // Почки. — 2014. — № 1. — С. 18-24.




DOI: https://doi.org/10.22141/2307-1257.0.1.07.2014.76548

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru